Issue Date: May 11, 2009
Ironwood Signs Pact With Spanish Firm
Ironwood Pharmaceuticals, based in Cambridge, Mass., has licensed to Spain's Laboratorios Almirall the European rights to develop and commercialize linaclotide, its investigational compound for irritable bowel syndrome. Almirall will pay $40 million up front plus potential precommercial licensing and milestone payments of up to $95 million. Ironwood would also receive royalties on sales in Europe.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society